Patent 9474780

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2016-01-06 · reel 036735/0675 · Assignment

    ALSINA-FERNANDEZ, JORGE; BOKVIST, BENGT KRISTER; COSKUN, TAMER; CUMMINS, ROBERT CHADWICKELI LILLY AND COMPANY

    Correspondent: BRENT W. DAHL

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Bengt Krister Bokvist (Eli Lilly and Co)
  • Tamer Coskun (Eli Lilly and Co)
  • Robert Chadwick Cummins (Eli Lilly and Co)
  • Jorge Alsina-Fernandez (Eli Lilly and Co)

All inventors appear to have been employed by Eli Lilly and Co at the time of filing. There are no immediate indications of unusual patterns like all inventors departing within 12 months.

Original assignee

Eli Lilly and Co.

Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products. They ship products embodying the claims of the patent, specifically tirzepatide (Mounjaro/Zepbound), which is a GIP and GLP-1 receptor co-agonist.
Current status: Operating.

Assignment timeline

  • 2016-01-06 (executed) / recorded 2016-01-06 — Reel 036735/0675
    • Conveyance: Assignment
    • Assignor: ALSINA-FERNANDEZ, JORGE; BOKVIST, BENGT KRISTER; COSKUN, TAMER; CUMMINS, ROBERT CHADWICK
    • Assignee: ELI LILLY AND COMPANY
    • Correspondent: BRENT W. DAHL, ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, INDIANAPOLIS, IN 46285.
    • Context: Internal transfer from inventors to employer.

The USPTO Patent Assignment Search (https://assignmentcenter.uspto.gov/) shows no further assignment records for US patent 9474780 beyond the initial assignment from the inventors to Eli Lilly and Company.

Timeline diagram

timeline
    title Ownership of US 9474780
    2016 : Application filed by Eli Lilly and Co
         : Assigned to Eli Lilly and Co
    2016 : Patent granted

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. The sole assignment is to Eli Lilly and Co, an operating pharmaceutical company.
  2. Known asserter in the chain — not present. Eli Lilly and Co is an operating company, not a known NPE.
  3. Repeat correspondent across the chain — not present. Only one assignment record exists, handled by the legal department of Eli Lilly and Co.
  4. Cascading transfers — not present. Only one assignment record is found.
  5. Pre-litigation transfer — not present. No litigation information is readily available in the patent data that would indicate a transfer within 6 months of a suit.
  6. Bankruptcy fire-sale — not present. Eli Lilly and Co is an active, operating company.
  7. Privateering — not present. No evidence of transfer to an NPE for assertion on behalf of Eli Lilly.
  8. Defensive aggregator (anti-NPE) — not present. The patent is held by Eli Lilly and Co, not a defensive aggregator.

Verdict

Insufficient data.
The only recorded assignment is from the inventors to Eli Lilly and Company. There are no subsequent assignments recorded at the USPTO, nor are there any public records indicating transfer to a known NPE or other entity that would suggest an assertion play. Therefore, it is presumed that Eli Lilly and Company remains the owner of the patent.

USPTO Assignment Center search for US9474780: https://assignmentcenter.uspto.gov/

Generated 5/21/2026, 12:47:06 PM